Beta-blockade in CHF: From contraindication to indication

European Heart Journal, Supplement

Volumn 8, Issue C, 2006, Pages

  Funck Brentano, Christian ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Bisoprolol; Carvedilol; Dose titration; Dose response; Metoprolol; Side effects

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; PLACEBO; RAMIPRIL;

ASTHMA; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; HYPOTENSION; INDIVIDUALIZATION; INOTROPISM; MAXIMUM TOLERATED DOSE; META ANALYSIS; MORBIDITY; MORTALITY; NORADRENALIN BLOOD LEVEL; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SUDDEN DEATH; SURVIVAL RATE; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS;

EID: 33750115350     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sul010     Document Type: Conference Paper

References (52)

1. Stock JP. Beta adrenergic blocking drugs in the clinical management of cardiac arrhythmias. Am J Cardiol 1966;18:444-449.
2. Rutenberg HL, Spann JF Jr. Alterations of cardiac sympathetic neurotransmitter activity in congestive heart failure. Am J Cardiol 1973;32:472-480.
3. Cohn JN, Levine TB, Francis GS, Goldsmith S. Neurohumoral control mechanisms in congestive heart failure. Am Heart J 1981;102: 509-514.
4. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
5. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990; 82:1724-1729.
6. Benedict CR, Shelton B, Johnstone DE et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD investigators. Circulation 1996;94:690-697.
7. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036.
8. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979;1:1374-1376.
9. Waagstein F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in dilated cardiomyopathy (MDC) trial study group. Lancet 1993; 342:1441-1446.
10. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994;90:1765-1773.
11. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
12. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 3:469-479.
13. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2009.
14. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N Engl J Med 1996; 334:1349-1355.
15. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-380.
16. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-1658.
17. The Beta-blocker Evaluation of Survival (BEST) Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-1667.
18. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225.
19. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
20. Fonarow GC, Chelimsky-Fallick C, Stevenson LW et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992;19:842-850.
21. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
22. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
23. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
24. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-677.
25. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669.
26. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
27. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.
28. The CIBIS II Scientific Committee. Design of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II). Fundam Clin Pharmacol 1997;11: 138-142.
29. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-218.
30. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.
31. Andreka P, Aiyar N, Olson LC et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002; 105:2429-2434.
32. Bouzamondo A, Hulot JS, Sanchez P, Cucherat M, Lechat P. Beta-blocker treatment in heart failure. Fundam Clin Pharmacol 2001;15:95-109.
33. Domanski MJ, Krause-Steinrauf H, Massie BM et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 2003;9:354-363.
34. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351-357.
35. Anderson JL, Lutz JR, Gilbert EM et al. A randomized trial of low-dose beta blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471-475.
36. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-546.
37. Cucchini F, Compostella L, Papalia D, de Domenico R, Iavernaro A, Zeppellini R. [Chronic treatment of dilated cardiomyopathy by beta blocking agents. Clinical and hemodynamic follow-up]. G Ital Cardiol 1988;18:835-842.
38. Fisher ML, Gottlieb SS, Plotnick GD et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-950.
39. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231.
40. Krum H, Sackner-Bernstein JD, Goldsmith RL et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995; 92:1499-1506.
41. Packer M, Colucci WS, Sackner-Bernstein JD et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-2799.
42. US Carvedilol Heart Failure Study Group. Carvedilol efficacy in severe heart failure. Proceedings of the Cardiorenal Advisory Panel Meeting of the Food and Drug Administration, 2 May 1996, Protocol 239.
43. Colucci WS, Packer M, Bristow MR et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94: 2800-2806.
44. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-1302.
45. McMurray JJ. Major beta blocker mortality trials in chronic heart failure: a critical review. Heart 1999;82 (Suppl. 4):IV14-IV22.
46. Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 2000; 84:615-619.
47. Wikstrand J, Hjalmarson A, Waagstein F et al. Dose of metoprolol CR/ XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-498.
48. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). Eur Heart J 2003;24: 552-559.
49. Funck-Brentano C, Lancar R, Hansen S, Hohnloser SH, Vanoli E. Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). Am Heart J 2001;142:989-997.
50. Schuchert A. Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians. Eur J Heart Fail 2005;7:604-611.
51. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-2318.
52. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.